Show Notes
In this episode, Eoin Tabb, a clinical cancer services pharmacist, unravels the complexities of immune checkpoint inhibitors (ICIs), the superheroes of cancer therapy. We'll explore how ICIs unleash the immune system to fight cancer, the potential side effects known as immune-related adverse events, and how healthcare professionals can effectively manage them. From common skin reactions and endocrine disruptions to rare neurological and cardiac complications, we'll cover it all. Tune in to understand how ICIs are revolutionizing cancer treatment while being prepared for their unique challenges
Introduction: Immune checkpoint inhibitors (ICIs) as revolutionary cancer treatments.
What are ICIs? How ICIs work by removing cancer's "invisibility cloak" to the immune system.
Immune-Related Adverse Events (irAEs): Explanation of irAEs as a side effect of overactive immune response.
Common irAEs:
Other irAEs: Neurological, cardiovascular, renal, hematologic, ocular.
Overlapping Syndromes: Myocarditis-myositis overlap, myasthenia gravis.
Management of irAEs:
Long-Term Management: Ongoing monitoring for late-onset or recurrent irAEs.
Emerging Therapies: Targeted therapies, personalized medicine.
Important Disclaimer: Consult healthcare providers for personalized guidance.
CPD IIOP Example: https://docs.google.com/document/d/1lI2B0iiLxYAHkvkWo8AjHvw-fjnCwc4DcioSiVF4Ptw/edit?usp=sharing
Feedback Form: https://forms.gle/AEcFAHCnykCNkKDJ9
References:
ESMO Guidelines: https://www.annalsofoncology.org/article/S0923-7534(22)04187-4/fulltext
More from Irish Haematology Oncology Podcast
Eoin Tabb reports from Day 3 of the ISOPP CAPhO 2025 Symposium in Victoria, Canada. This episode delves into crucial discussions on Equity, Diversity, and Inclusion (EDI) in pharmacy practice, the benefits and risks of Artificial Intelligence (AI) in oncology, updates on preventing Cancer-Associated Thrombosis (CAT), and the implementation of pre-therapeutic Pharmacogenomics (PGx), including combining DPYD testing with Therapeutic Drug Monitoring (TDM) for 5-FU. Plus, hear exciting news from the ISOPP AGM about next year's unique 24-hour virtual conference format and a special collaboration with the Irish Pharmacy Haematology Oncology Society (IPHOS)! #ISOPPCAPhO2025 #OncologyPharmacy #Haematology #ClinicalPharmacy #EDI #AI #PGx #TDM #CAT CAT Survey: https://redcap.alfredhealth.org.au/redcap/surveys/index.php?s=dFo7DpNgVBauTYeW&__startover=1
Join Eoin Tabb for the second daily dispatch from the ISOPP CAPhO 2025 Symposium in Victoria, Canada. Day 2 covered a wide spectrum of crucial topics for haematology/oncology pharmacy practice. Highlights include practical management strategies for PARP inhibitors, the importance of cultural humility and discussing traditional medicines, ISOPP's new global service level framework, pharmacy's role in disaster preparedness and environmental sustainability, efficiencies in myeloma treatment administration (pre-meds, infusion times, schedules), managing CMV infections, considerations for treating older/unfit patients using geriatric assessment, and critical updates on hazardous drug lists and safety. Tune in for key insights and takeaways relevant to Irish practice! #ISOPPCAPhO2025 #OncologyPharmacy #Haematology #ClinicalPharmacy PARPi Clinical Resource: https://cdn.ymaws.com/www.cano-acio.ca/resource/resmgr/endorsements/en_parp_inhibitor_clinical_r.pdf
Join host Eoin Tabb for a special dispatch episode recorded live from the ISOPP 2025 Symposium in Victoria, BC. Get your 'audio delegate bag' with key insights from Day 1, covering: